Broncus Holding Corporation (BRNHF)

0,0800 0,0000 (0,00%) Börsenschluss: 02:52PM EDT

Broncus Holding Corporation

Building 8
8th Floor, Room 801 No. 88 Jiangling Road, Xixing Street Binjiang District
Hangzhou
China

https://www.broncus.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 308

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Hong Xu	CEO & Executive Director	214k	N/A	1986
Thomas M. Keast	VP, Operation Director & Scientist in resident	N/A	N/A	N/A
Feng Yao	Sr. Accountant	N/A	N/A	N/A
Ms. Elaine Lu	Director of Finance & Administration	N/A	N/A	N/A
Ms. Yin Kwan Ho	Company Secretary	N/A	N/A	1977

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy. In addition, the company provides diagnosis products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. The company was incorporated in 2012 and is headquartered in Hangzhou, China.

Corporate Governance

Broncus Holding Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.